Reviewer's report

**Title:** A survivor of childhood medulloblastoma presenting with growth hormone-induced edema and inflammatory lesions: case report.

**Version:** 3  **Date:** 12 May 2008

**Reviewer:** frappaz didier

I am familiar with the literature and believe that this case meets one of the 9 criteria for evaluation in the journal: Unreported or unusual side effects or adverse interactions involving medications

**Has the case been reported coherently?:** Yes

**Is the case report authentic?:** Yes

**Is this case worth reporting?:** Yes

**Is the case report persuasive?:** No

**Does the case report have explanatory value?:** Yes

**Does the case report have diagnostic value?:** Yes

**Will the case report make a difference to clinical practice?:** Yes

**Is the anonymity of the patient protected?:** Yes

**Comments to authors:**

The case reported here deals with a child treated for a metastatic medulloblastoma with high dose chemotherapy and cranio spinal RT.

As the child was in CR, he was treated with GH, but an increase in the iatrogenic lesions (RT+highdose CT induced) was seen and could be reversed by tapering the doses of GH.

Though not a definitive proof of efficacy, the temporal changes are compatible with such an interaction.

This publication has the merit of suggesting that GH treatment warrants multidisciplinary discussion in patients who have post RT+highdose therapy induced lesions.

Authors are encouraged to expand on the hypothesis underlying the RT+highdose iatrogenic changes, to explain why this was never described in standard patients.
Declaration of competing interests:

I declare that I have no competing interests.